Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809290 | 0.80 | ABL1 (0.50) | GRM5ABL1RORCCYP1A2CYP3A4 | |
| SCHEMBL31420103 | 0.75 | LMNA (0.49) | GRM5RORCCYP1A2KDRCYP3A4 | |
| SCHEMBL209579 | 0.75 | LMNA (0.49) | GRM5RORCCYP1A2KDRCYP3A4 | |
| SCHEMBL19962825 | 0.73 | LMNA (0.53) | CYP1A2TGFBR1CYP3A4CYP2C9LMNA | |
| SCHEMBL26085118 | 0.70 | RORC (0.49) | GRM5RORCATMLMNAMAPT | |
| SCHEMBL25240657 | 0.67 | LMNA (0.49) | CYP1A2KDRCYP3A4CYP2C9AR | |
| SCHEMBL25171584 | 0.65 | NR3C2 (0.54) | CYP1A2CYP3A4CYP2C9ARLMNA | |
| SCHEMBL2035487 | 0.65 | LMNA (0.68) | CYP1A2LMNAMAPTCYP2C19 | |
| SCHEMBL18785787 | 0.65 | LMNA (0.53) | ABL1CYP1A2CYP3A4CYP2C9LMNA | |
| SCHEMBL19890689 | 0.65 | L3MBTL1 (0.55) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544106-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544106-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | GRM5 3535/4885ABL1 7/4885RORC 1182/4885 |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | GRM5 3535/4885ABL1 7/4885RORC 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.